Hermes Vector

Science

Glucose-powered implant tested in rat models of diabetes

A Nature news article reports that a bioelectronic device called NeuroAxis lowered blood glucose in rat models of diabetes by stimulating the vagus nerve when blood sugar was high.

By Hermes Vector

Also in: Español · Português · Français · Deutsch · हिन्दी

Checked against 1 sourceNature
Illustration for: Glucose-powered implant tested in rat models of diabetes

In brief

  • A bioelectronic device called NeuroAxis lowered blood glucose in rat models of diabetes.
  • The device stimulates the main nerve between the brain and internal organs when blood sugar is high.
  • Diabetes develops when insulin activity is insufficient to maintain healthy blood glucose levels.
  • The work is described as proof of principle in a Nature news article by Junta Imai.

Glucose-powered implant tested in rat models of diabetes

A device that stimulates the main nerve between the brain and the internal organs when blood sugar is high is an effective therapy in rat models of diabetes, according to a Nature news article by Junta Imai published on 18 November 2026.

Background on diabetes

Hundreds of millions of people around the world are affected by diabetes mellitus. The condition develops when the activity of insulin, a glucose-lowering hormone secreted by pancreatic β-cells, becomes insufficient to maintain healthy glucose levels in the blood. Diabetes can be managed with oral medication or by injecting insulin and other metabolic hormones, but the constant need for people with diabetes to manage their lifestyle and blood-glucose levels can impair their quality of life. Therapeutic approaches that monitor and control blood glucose automatically are therefore highly desirable.

The NeuroAxis device

Writing in Nature, Xiu et al. report proof of principle of a bioelectronic device called NeuroAxis that monitors and controls blood glucose automatically in rat models of diabetes. The device stimulates the main nerve between the brain and the internal organs when blood sugar is high. The Nature news article describes this as an effective therapy in rat models of diabetes.

Related research

The news article cites several related studies, including work by Katsarou et al. in Nature Reviews Disease Primers, DeFronzo et al. in Nature Reviews Disease Primers, Pavlov and Tracey in Nature Reviews Endocrinology, Imai and Katagiri in International Immunology, Imai et al. in Science, Yamamoto et al. in Nature Communications, Kawana et al. in Nature Biomedical Engineering, Imai and Katagiri in Trends in Endocrinology and Metabolism, and Cotero et al. in Nature Biomedical Engineering.

Why it matters

The research represents a proof of principle for automatic blood-glucose control in animal models. If the approach translates to humans, it could reduce the daily management burden for people with diabetes. The Nature news article does not report any timeline for human testing, any regulatory status, or any plans for commercial development.


Sources

This article was drafted with AI assistance and checked against the sources above. Company claims are reported as claims. Cover image is AI-generated.

Questions readers ask

What is the NeuroAxis device and how does it work?
The NeuroAxis is a bioelectronic device that monitors and controls blood glucose automatically by stimulating the main nerve between the brain and the internal organs when blood sugar is high.
Who published the news article about this device and when?
Junta Imai published the Nature news article on 18 November 2026.
In which animal models was the device tested?
The device was tested in rat models of diabetes.
Does the article provide a timeline for human testing?
No, the Nature news article does not report any timeline for human testing, any regulatory status, or any plans for commercial development.

The day's checked news, by email

One short email a day with the top stories. Free, and you can unsubscribe in one click.

Or follow for the latest news:

How do you feel about this story?

Comments 0

No comments yet. Start the discussion.